Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Dermatologic 1CNS 1

Conditions

Thyroid Neoplasms 1Sedation 1Sarcoma, Synovial 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Parasomnias 1Pain, Postoperative 1Neoplasm Metastasis 1Melanoma 1Leiomyosarcoma 1Glioma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Anxiety Disorders 1

Interventions

Magnetic Resonance Spectroscopy 4Surgical Procedures, Operative 3Iodine-131 3Iodine-124 3Biopsy 3selpercatinib 2lenvatinib 2Watchful Waiting 2Thyrotropin Alfa 2Therapeutics 2Nivolumab 2Fluorodeoxyglucose F18 2Cyclophosphamide 2Cetuximab 2Biopsy, Fine-Needle 2trastuzumab deruxtecan 1trametinib 1sintilimab 1sacituzumab govitecan 1repotrectinib 1pralsetinib 1pembrolizumab 1gallium Ga 68 dotatate 1fludarabine phosphate 1defactinib 1dabrafenib 1cemiplimab 1brodalumab 1binimetinib 1anlotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Thyroid Neoplasms × Midazolam × Clear all
NCT05355701 2026-05-14

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

Pfizer

Phase 1 Recruiting
267 enrolled
CNSDermatologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Glioma, Melanoma, Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡